Merck, 699855P-25MG, 3D-(6-acyl) PHAD™</SUP>

General description
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
Application
3D-(6-acyl) PHAD™ has been used:
as a synthetic adjuvant in human papillomavirus (HPV) and virus-like particles (VLPs)-based HPV vaccine preparations
as a component of liposomes for immunizing mice with P. falciparum (Pfs25) malaria transmission-blocking vaccine antigen candidate
in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice

Packaging
2 mL Amber Glass Crimp Cap Vial (699855P-1mg)
2 mL Amber Glass Crimp Cap Vial (699855P-5mg)
5 mL Amber Glass Screw Cap Vial (699855P-10MG);5 mL Amber Glass Screw Cap Vial (699855P-25MG)
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC